Oxford–AstraZeneca COVID-19 vaccine
Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca
Oxford–AstraZeneca COVID-19 vaccine ▸ Facts ▸ Comments ▸ News ▸ Videos
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
| 0 shares | ShareTweetSavePostSend |
You Might Like
1 in 3 Covaxin recipients hit by adverse events: StudyNearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual..IndiaTimes - Published | |
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recallUK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped..IndiaTimes - Published | |
'Manufacturing of Covishield ceased two years back due to poor demand'IndiaTimes - Published | |
SII stopped manufacturing Covishield since December 2021, says 'disclosed side effects details in packaging insert'SII stopped Covishield extra doses due to lawsuit, disclosed rare Thrombosis. Advocates govt collaboration. AstraZeneca withdraws Vaxzevria marketing authorisations globally. European Medicines Agency..IndiaTimes - Published | |
55% Covidshield recipients had mild side effects: AMCH studyIndiaTimes - Published | |
AstraZeneca admits Covishield vaccines raises rare side-effects risk. How worried should you be?In India, almost 90% of people who received Covid vaccine, received the AstraZeneca vaccine which in India is called Covishield.DNA - Published | |
Take down defamatory posts on Covishield: Bombay high courtIndiaTimes - Published | |
Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HCThe Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and..IndiaTimes - Published | |
SII to restart vaccine production amid surge in Covid casesSerum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus..IndiaTimes - Published | |
Serum Institute of India restarts manufacturing of Covid-19 vaccine CovishieldSerum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the..IndiaTimes - Published | |
Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per doseCovovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax..IndiaTimes - Published | |
Drug panel favours nod for Covovax as Covid boosterAn expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..IndiaTimes - Published | |
Covovax may get approval as heterologous boosterThe government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..IndiaTimes - Published | Covid-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar PoonawallaSerum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the..IndiaTimes - Published |
Serum Institute to provide 2 crore Covishield doses to central govt free of costIndiaTimes - Published | No shortage of Covishield, says PoonawallaIndiaTimes - Published |
Bill Gates, SII get Bombay High Court notice as petitioner claims Covishield killed his daughterThe petitioner blamed the authorities for creating false narratives about the Covishield vaccine. He has sought compensation of Rs 1,000 crore.DNA - Published | Govt: Sputnik V recipients can take Covishield, Covaxin boosterIndiaTimes - Published |
Corbevax gets nod as booster after Covishield, Covaxin shotsIndiaTimes - Published | India to start Covid mix-and-match booster vaccines on FridayIndia said on Wednesday that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's..IndiaTimes - Published |
Biological E's Corbevax approved as booster dose for adults vaccinated with Covaxin, CovishieldThis is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in India.DNA - Published Also reported by •IndiaTimes | Govt nod for Corbevax as booster for adults vaccinated with Covishield, Covaxin soonIndiaTimes - Published |
Health ministry seeks 5 crore free Covishield doses from GAVI under COVAXThe Union health ministry has asked global vaccine alliance GAVI to supply 5 crore of the allocated 10 crore doses of Covishield to India under the COVAX facility free of cost, official sources said on..IndiaTimes - Published | Corbevax being considered as booster dose for Covishield, Covaxin jabbed peopleNTAGI is considering using Corbevax as a booster vaccination against Covid-19.DNA - Published |
NTAGI to discuss allowing Corbevax as booster shot for Covishield, Covaxin recipients: SourcesAllowing Biological E's Corbevax as a booster for those fully vaccinated against Covid-19 with either Covishield or Covaxin and reducing the gap between the second dose and the precaution dose of the..IndiaTimes - Published | Corbevax maker seeks emergency use approval as booster jab for adults vaccinated with Covishield, CovaxinThere were 416 patients aged 18 to 80 who got two doses of Covaxin or Covishield, the last one six months before the Corbevax booster.DNA - Published |
Breakthrough Delta infection, reinfection with Omicron in person vaccinated with CovishieldThe patient received the first dose of Covishield vaccine on January 31, 2021, and the second dose on March 3, 2021.DNA - Published | Covid Update: Get Covaxin, Covishield at Rs 225Price slash of Covaxin and Covishield was announced after the government allowed all above 18 years of age can get booster dose from April 10.DNA - Published |
Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shotIndiaTimes - Published | Covishield, Covaxin prices slashed ahead of booster drive expansionSerum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..IndiaTimes - Published |
Serum Institute of India prices Covishield booster dose at Rs 600SII CEO Adar Poonawalla also welcomed the government's move to allow precautionary doses of the vaccine to all aged above 18 years.DNA - Published | Serum Institute's Covishield precaution dose priced at Rs 600 per shotVaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.IndiaTimes - Published |
ICMR study shows increase in antibodies after receiving Covaxin booster dose, says MoS HealthInternational data available on booster doses of AstraZeneca & Covishield suggests 3 to 4 fold increase in antibody levels after their administration.DNA - Published | As cases rise elsewhere, govt set to cut Covishield shots gapThe government’s top vaccination advisory panel, National Technical Advisory Group on Immunisation (NTAGI), has recommended reducing the interval between the two primary doses of Covishield to 8-16..IndiaTimes - Published |
Gap between first and second Covishield vaccine doses reduced to 8-16 weeksPresently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.DNA - Published | Second Covishield dose can be given between 8-16 weeks after first dose, says NTAGI reducing gapIndiaTimes - Published |
Mixing Covishield & Covaxin gives better immunity: ICMRIndiaTimes - Published | SII urges Mandaviya to reduce gap between 2nd, precaution dose of Covishield from 9 to 3 monthsIndiaTimes - Published |
Media reports claiming 50 lakh unused Covishield doses may go waste by month end 'misleading': GovtThe Union health ministry on Thursday refuted as “misleading” media reports which claimed that 50 lakh unused Covishield doses may go waste by the end of this month. It said the Centre had..IndiaTimes - Published | Serum Institute has applied for full market authorisation of Covishield: CEO Adar PoonawalaSerum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for its Covishield vaccine, company's CEO Adar Poonawalla..IndiaTimes - Published |
India-Bangladesh bonhomie scaled new heights as 2021 marked 50 years of tiesThe year began on a promising note as Bangladesh PM Sheikh Hasina thanked her Indian counterpart Narendra Modi for sending over two million doses of AstraZeneca-Oxford University vaccine Covishield, as..IndiaTimes - Published | Covishield cover high 7 months after 2 doses, 90% antibody prevalence seen: StudyIndiaTimes - Published |
Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: GovtIndiaTimes - Published | ICMR focus on two-dose vax, is fine with current Covishield gapIndiaTimes - Published |
Government panel rejects SII's plea to administer a third dose of Covishield vaccineSII sought approval to administer the third dose on the basis of adequate stock of Covishield and rising demand for boosters amid emergence of OmicronDNA - Published | CDSCO panel seeks local clinical trial data from SII for approval of Covishield as booster doseIndiaTimes - Published |
Subject Expert Committee to meet on Dec 10 to discuss approval for Covishield booster doseIndiaTimes - Published | Not enough orders, may cut Covishield output by 50%: SIIWith not enough orders for Covishield from the Centre, Serum Institute of India CEO Adar Poonawalla on Tuesday said the company is looking at slashing monthly production of vaccines by at least 50% %...IndiaTimes - Published |
Covid-19: A wide range of vaccines act as booster to AstraZeneca, Pfizer shots, says studyUp to six different Covid-19 boosters were found to be safe, and provoked strong immune responses in people who have previously received a two-dose course of the Oxford-AstraZeneca-developed..IndiaTimes - Published | As Omicron fear intensifies, Serum Institute of India seeks DCGI's approval for Covishield booster shotRecently, Kerala, Rajasthan, Karnataka, and Chhattisgarh have also urged the Centre to decide on allowing booster doses of the COVID-19 vaccine.DNA - Published |
